Luna-Ortiz Pastor, Torres Juan Carlos, Pastelin Gustavo, Martínez-Rosas Martín
Department of Pharmacology. Instituto Nacional de Cardiología Ignacio Chávez, México, D.F.
Arch Cardiol Mex. 2011 Jan-Mar;81(1):33-46.
"Recently, it has been shown that the heart can be protected against the ischemia-reperfusion injury if brief coronary occlusions are performed just at the beginning of the reperfusion. This procedure has been called postconditioning (PostC). It can also be elicited by pharmacological interventions, which are named pharmacological PostC. In general, PostC reduces the reperfusion- induced injury, blunts oxidant-mediated damages and attenuates the local inflammatory response to reperfusion, decreases infarct size, diminishes apoptosis, neutrophil activation, and endothelial dysfunction. The mechanisms that participate in PostC are still not completely understood. In this regard, adenosine, glycine, bradykinin, ciclosporin A are involved in PostC triggering. Similar to ischemic preconditioning, PostC triggers several signaling pathways and molecular components, including nitric oxide (NO), protein kinase C, adenosine triphosphate-sensitive potassium channels, the Reperfusion Injury Salvage Kinases (RISK) pathway, which comprises phosphatidylinositol-3-OH kinase (PI3K) and extracellular signal-regulated kinase (ERK 1/2), and, finally, the Survivor Activating Factor Enhancement (SAFE) pathway. In this review, we describe the mechanisms of reperfusion-induced injury as well as the proposed protective pathways activated by PostC, which seem to converge in inhibition of mitochondrial permeability transition pores opening. On the other hand, experimental evidence indicates that volatile anesthetics and opioids are capable of exerting cardioprotective effects under certain conditions, constituting a very useful pharmacological PostC. Thus, the first minutes of reperfusion represent a window of opportunity for triggering the aforementioned mediators, which acting in concert lead to protection of the myocardium against reperfusion injury. Pharmacological, especially anesthetic, PostC may have a promising future in the clinical scenarios in the operating room."
最近研究表明,如果在再灌注开始时进行短暂的冠状动脉闭塞,心脏可免受缺血再灌注损伤。此过程被称为后适应(PostC)。它也可由药理学干预引发,称为药理学后适应。一般来说,后适应可减轻再灌注诱导的损伤,减轻氧化介导的损伤,并减弱对再灌注的局部炎症反应,减小梗死面积,减少细胞凋亡、中性粒细胞活化及内皮功能障碍。参与后适应的机制仍未完全明了。在这方面,腺苷、甘氨酸、缓激肽、环孢素A参与后适应的触发。与缺血预处理相似,后适应触发多种信号通路和分子成分,包括一氧化氮(NO)、蛋白激酶C、三磷酸腺苷敏感性钾通道、再灌注损伤挽救激酶(RISK)通路(其包含磷脂酰肌醇-3-羟基激酶(PI3K)和细胞外信号调节激酶(ERK 1/2)),最后是存活激活因子增强(SAFE)通路。在本综述中,我们描述了再灌注诱导损伤的机制以及后适应激活的拟议保护通路,这些通路似乎都汇聚于抑制线粒体通透性转换孔的开放。另一方面,实验证据表明挥发性麻醉剂和阿片类药物在某些条件下能够发挥心脏保护作用,构成一种非常有用的药理学后适应。因此,再灌注的最初几分钟代表了触发上述介质的机会窗口,这些介质协同作用可保护心肌免受再灌注损伤。药理学后适应,尤其是麻醉学后适应,在手术室的临床场景中可能具有广阔的前景。